GAMMA Investing LLC Boosts Stock Position in MediWound Ltd. (NASDAQ:MDWD)

GAMMA Investing LLC increased its stake in shares of MediWound Ltd. (NASDAQ:MDWD) by 1,507.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,816 shares of the biopharmaceutical company’s stock after purchasing an additional 1,703 shares during the quarter. GAMMA Investing LLC’s holdings in MediWound were worth $28,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its position in MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,162 shares in the last quarter. Bank of America Corp DE increased its position in MediWound by 38.0% during the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 2,178 shares in the last quarter. Rhumbline Advisers increased its position in MediWound by 7.3% during the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 739 shares in the last quarter. MGO One Seven LLC purchased a new stake in MediWound during the 4th quarter worth about $216,000. Finally, Barclays PLC increased its position in MediWound by 11.2% during the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 1,249 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

Wall Street Analysts Forecast Growth

MDWD has been the topic of a number of research analyst reports. HC Wainwright set a $31.00 price target on MediWound and gave the stock a “buy” rating in a research note on Thursday, May 22nd. Alliance Global Partners initiated coverage on MediWound in a report on Friday, May 2nd. They set a “buy” rating and a $25.00 target price on the stock. Craig Hallum began coverage on MediWound in a report on Friday, February 28th. They set a “buy” rating and a $39.00 price objective on the stock. Wall Street Zen upgraded MediWound to a “sell” rating in a report on Friday, March 21st. Finally, Oppenheimer began coverage on MediWound in a report on Monday, June 2nd. They issued an “outperform” rating and a $34.00 price target for the company. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, MediWound currently has an average rating of “Moderate Buy” and a consensus price target of $31.80.

MediWound Stock Down 0.7%

Shares of MediWound stock opened at $19.39 on Friday. The firm has a market cap of $209.61 million, a price-to-earnings ratio of -9.28 and a beta of 0.38. The business has a fifty day simple moving average of $19.53 and a 200-day simple moving average of $18.19. MediWound Ltd. has a fifty-two week low of $14.14 and a fifty-two week high of $24.00.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.58. MediWound had a negative return on equity of 74.12% and a negative net margin of 110.45%. The business had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. During the same quarter in the prior year, the firm posted ($1.05) earnings per share. Analysts anticipate that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.